Vera Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$315.5M | -$167.2M | -$102.0M | -$90.9M | -$34.4M |
| Operating expenses | $315.5M | $167.2M | $102.0M | $90.9M | $34.4M |
| Cash from operations | -$241.1M | -$134.7M | -$92.2M | -$67.6M | -$23.7M |
| Capital expenditure | $630,000 | $972,000 | $63,000 | $62,000 | $0 |
| Free cash flow | -$241.7M | -$135.7M | -$92.2M | -$67.7M | -$23.7M |
| Share repurchases | $0 | $13,000 | $0 | — | — |
| Impairments | $0 | $0 | $0 | — | — |
| Total assets | $734.7M | $655.7M | $175.5M | $131.4M | $83.7M |
| Total liabilities | $130.2M | $78.5M | $73.9M | $54.5M | $14.2M |
| Total debt | $75.0M | $50.0M | $50.0M | $25.0M | $5.0M |
Shares outstanding 71.8M · Free float 63.6%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.